EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Rituximab‐responsive epilepsia partialis continua in autoimmune Polyendocrine syndrome: A video‐ EEG – EMG polygraphic study

Angelo Pascarella, Fabio Rossini, Chiara Ferrazzoli, Markus Leitinger, Giorgi Kuchukhidze, Gudrun Kalss, Eugen Trinka

Epileptic Disorders · 2026-11-20

DOI: 10.1002/epd2.70481 ↗

At a glance

Journal article in Epileptic Disorders, published online on 2026-11-20. Written by Angelo Pascarella and 6 co-authors. 16 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Epilepsia partialis continua (EPC) is a rare and challenging form of focal motor status epilepticus. Its occurrence strictly in systemic autoimmune disorders without overt encephalitis is exceptional. Corticosteroids are first‐line therapy but may be limited by significant side effects and poor metabolic tolerability. We report a 54‐year‐old woman with Autoimmune Polyendocrine Syndrome (APS), including autoimmune hepatitis, latent autoimmune diabetes in adults, celiac disease, and hypothyroidism, presenting with continuous jerks of right III‐V fingers. Neurological examination showed continuous, irregular jerks confined to the right III, IV, and V fingers. Extensive serum and CSF screenings, including neuronal antibodies, and MRI were unremarkable. Ictal HMPAO‐SPECT revealed a focal hyperperfusion in the left hand‐knob area of the primary motor cortex. Brain FDG‐PET revealed focal hypometabolism in the same region. Video‐EEG–EMG polygraphy showed intermittent spikes and polyspikes over the left central region preceding EMG bursts of the right V finger's abductor muscle with a latency of approximately 30–40 ms. These findings were consistent with EPC. Corticosteroids induced marked improvement but were discontinued due to severe glycemic worsening. Subsequent treatment with oral steroids, IVIG, and multiple antiseizure medications were ineffective. Administration of Rituximab led to complete and sustained clinical and electrophysiological remission, which persisted at the 18‐month follow‐up. EPC can be a severe, focal manifestation of systemic autoimmunity even without encephalitis. Rituximab represents an effective steroid‐sparing option for refractory autoimmune EPC, particularly in metabolically vulnerable patients.

Cite

APA

Pascarella, A., Rossini, F., Ferrazzoli, C., Leitinger, M., Kuchukhidze, G., Kalss, G., & Trinka, E. (2026). Rituximab‐responsive epilepsia partialis continua in autoimmune Polyendocrine syndrome: A video‐ EEG – EMG polygraphic study. Epileptic Disorders. https://doi.org/10.1002/epd2.70481

Vancouver

Pascarella A, Rossini F, Ferrazzoli C, Leitinger M, Kuchukhidze G, Kalss G, et al. Rituximab‐responsive epilepsia partialis continua in autoimmune Polyendocrine syndrome: A video‐ EEG – EMG polygraphic study. Epileptic Disorders. 2026. doi:10.1002/epd2.70481

BibTeX
@article{Pascarella2026,
  author = {Pascarella, Angelo and Rossini, Fabio and Ferrazzoli, Chiara and Leitinger, Markus and Kuchukhidze, Giorgi and Kalss, Gudrun and Trinka, Eugen},
  title = {Rituximab‐responsive epilepsia partialis continua in autoimmune Polyendocrine syndrome: A video‐ EEG – EMG polygraphic study},
  journal = {Epileptic Disorders},
  year = {2026},
  doi = {10.1002/epd2.70481}
}
Start for free →